Navigation Links
Cynosure Introduces Higher Power Smartlipo(TM) LaserBodySculpting Workstation

WESTFORD, Mass., Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the launch of a new, higher power Smartlipo LaserBodySculpting (SM) Workstation. The new 10-watt workstation is intended for high-volume aesthetic laser practices, allowing a physician to complete a typical laser-assisted liposuction procedure in about half the time as the original 6-watt workstation.

"Cynosure's new 10-watt Smartlipo workstation allows me to treat patients quickly and efficiently, with the same level of safety and efficacy as the 6- watt system," said Bruce Katz, M.D., founder of New York's Juva Skin & Laser Center. "For example, an area of localized fat under the chin can be treated in about eight minutes with the 10-watt Smartlipo system, compared with about 15 minutes with the 6-watt workstation."

Introduced by Cynosure in January, the minimally invasive Smartlipo workstation is an innovative system designed as an alternative to traditional liposuction in patients with smaller areas of localized fat. The system's proprietary pulsing format delivers laser energy that liquefies localized deposits of fat that is then removed through a cannula.

In addition the laser energy coagulates the tissue, thereby sculpting body contours and tightening the skin. The procedure generally causes less bleeding, swelling and bruising than traditional liposuction, resulting in fewer complications and faster recovery. Cynosure received U.S. Food and Drug Administration clearance to market Smartlipo in the fourth quarter of 2006.

According to cosmetic surgeon Robert Gotkin, M.D., co-director of Cosmetique in New York, "The introduction of its new, higher power Smartlipo reflects Cynosure's commitment to advance its customers' practices with innovative products designed for patient efficiency."

"We believe the introduction of the 10-watt platform will acc elerate the adoption of Smartlipo in the marketplace," said Cynosure President and Chief Executive Officer Michael Davin. "We have been very pleased with the response to Smartlipo. Due to the short and minimally invasive nature of the Smartlipo treatment, patients who may have never considered traditional liposuction are having Smartlipo procedures performed."

"We believe that expanding our family of products with a more powerful version of the Smartlipo workstation will enhance our competitive position," Davin said. "The faster treatment times afforded by this 10-watt platform will be attractive to medical professionals, particularly those with high- volume practices."

The 10-watt Smartlipo workstation is available as a standalone unit or as an upgrade to the 6-watt system. Cynosure previously announced that it has added a 10-person specialty surgical sales force to market its Smartlipo family of workstations in North America.

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite.

Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.


'"/>




Related medicine news :

1. TI Cycles Introduces Foldman
2. Canada Introduces Mandatory Nutrition Labeling
3. Cuba Introduces New Device for Detecting Vascular Diseases
4. China Introduces Solar-powered Baths
5. Allergan Introduces ‘Dermal Filler’ for Smile Lins
6. UAE Introduces Cervical Cancer Vaccine
7. Iceland Introduces Smoking Ban in Bars and Restaurants
8. Higher Risk of Asthma in children with autoimmune disease
9. Death Risk Higher in Obese Women with Colon Cancer
10. Women With Diabetes Have a Higher Risk of Depression
11. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... , ... Cellairis is a worldwide mobile device and computer repair franchise that ... and Samsung Galaxy devices with premium parts and accessories. Cellairis has recently set-up ... accessibility for customers. While customers do their shopping, Cellairis can accomplish a number of ...
(Date:12/9/2016)... ... ... An inventor from Cana, Va., wanted to fulfill the need for a ... , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. It is ... in a matter of minutes, or even seconds. The SAFETY STRAP FOR AMPUTEES is ...
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
(Date:12/8/2016)... Islandia, NY (PRWEB) , ... December 08, 2016 ... ... company, is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture ... published in JMIR Medical Informatics . , Results of the comparative usability ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Research and Markets has announced the addition of the "Endodontic Supplies ... ... the worldwide markets for Endodontic Supplies in US$ Thousand. The report provides separate ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a six-year ...
(Date:12/8/2016)... Dec. 8, 2016   TriNetX , the ... Children,s Hospital signed a membership agreement to ... development of new cures. The TriNetX ... 57 million patients globally, biopharmaceutical companies and contract ... improve protocol design, site selection, patient recruitment, and ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: